DuPont narrows the gap in US infant nutrition

DuPont Nutrition & Health welcomes US clearance of CARE4U 2´-fucosyllactose (2’-FL), a human milk oligosaccharide (HMO) that can help narrow the nutritional gap between breast milk and formula.

The positive response by the US Food and Drug Administration to DuPont’s GRAS notice means infant formula manufacturers can confidently use CARE4U 2’-FL in infant and toddler formulas to mimic some of the health-promoting benefits of the HMOs naturally present in human milk. CARE4U 2´-FL HMO gained EU approval as a novel food from the beginning of 2018.

After lactose and lipids, HMOs are the third-most-abundant solid component of human milk. Today, there is considerable evidence that HMOs in human milk support digestive, immune and cognitive development by modifying the gut microbiota.

Research indicates that use of DuPont’s commercial ingredient CARE4U 2’FL HMO can bring some of the same health benefits to infant formula.

“Human milk remains the best option for nourishing infants, but not all mothers are able to breast-feed their babies. In such cases, it is essential that infant formula is a close second-best. CARE4U 2’FL HMO can help narrow the gap between human milk and infant formula,” says Steen Lyck, global business director for HMO, DuPont Nutrition & Health.

CARE4U 2’FL HMO contains more than 98% 2’-fucosyllactose, the most abundant of the more than 130 oligosaccharides in human milk making it the purest HMO product on the market today, Du Pont says.

“We have developed CARE4U 2’-FL in collaboration with our partner Inbiose, who developed the ingredient by microbial fermentation, a process that DuPont has since improved and commercialised. Superior powder properties (high purity and density), make it easy to use in formulations,” Lyck concludes.

Related content

Leave a reply

Dairy Industries International